"CGIE (TM) is being built as future-facing infrastructure rather than a point solution," said Yusuf Henriques, Founder and CEO of IndyGeneUS Bio. "Our objective is to establish the AI×Bio Factory--the ...

Variant Bio, a genomics-driven AI drug discovery company, today announced the launch of Inference, the world's first agentic genomic drug dis ...

Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for ...

Demonstrating faster, simpler, more cost-efficient NGS workflows that turn complex agrigenomics data into practical ...

Explore the groundbreaking AI genomics platform, Inference, launched by Variant Bio to enhance drug discovery using genetic ...

The BIOSECURE Act (H.R. 8333), introduced in May 2024, is a critical piece of legislation designed to safeguard sensitive genomic data and biotech infrastructure from foreign exploitation. The bill ...

Built on AWS, an Asia-led initiative is testing a new way to detect outbreaks earlier by sharing intelligence across borders without sharing sensitive health data.

The Centre of Genomics integrates national referral laboratories, NGS platforms and clinical expertise across specialties ...

The company said the Centre of Genomics will be supported by two CAP-accredited genomics laboratories located in Mumbai and ...

Metropolis Healthcare opens Centre of Genomics to scale precision diagnostics and advance research in India: Our Bureau, Bengaluru Tuesday, January 13, 2026, 12:30 Hrs [IST] Metro ...

IndyGeneUS Bio today announced the filing of a patent application covering its Clinico-Genomic Insight Engine™ (CGIE™)—a foundational platform under development to support regulated whole-genome ...